Skip to main content
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · INM ISIN · CA4576375022 LEI · 549300VA5DNHEJGHG397 US Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2026-05-19 M&A Activity
Country CA Canada
Listing US INM

About InMed Pharmaceuticals Inc.

https://www.inmedpharma.com/

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that target the CB1 and CB2 cannabinoid receptors. The company's therapeutic pipeline includes preclinical programs for Alzheimer's disease (INM-901) and dry age-related macular degeneration (INM-089). In dermatology, InMed has completed a Phase 2 clinical trial for the treatment of epidermolysis bullosa. Additionally, its subsidiary, BayMedica, manufactures and supplies high-purity, rare cannabinoids such as cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), and cannabidivarin (CBDV) as raw ingredients for the business-to-business health and wellness market.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
M&A Activity Classification · 85% confidence The document is a Form 8-K current report announcing the entry into a material definitive agreement – specifically an Agreement and Plan of Merger with Mentari Therapeutics, including detailed merger and financing terms. This is a direct announcement of M&A activity (merger proposal), not a full proxy statement or a standalone financial report. Therefore it fits the M&A Activity category.
2026-05-19 English
FORM 8-K
Regulatory Filings Classification · 91% confidence The document is a U.S. SEC Form 8-K “Current Report” describing material events (entry into a material definitive agreement amending preferred investment options, press release, exhibits). It is a regulatory filing under the Securities Exchange Act, not a standalone audit, earnings release, proxy, or financial report. Thus it best fits the “Regulatory Filings” category (RNS).
2026-05-19 English
10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Interim / Quarterly Report Q3 2026
2026-05-06 English
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes references to an At The Market Offering Agreement, a prospectus supplement, and legal opinions related to the sale of common shares. It does not contain detailed financial statements or comprehensive financial analysis. The document is relatively short (4597 characters) and primarily serves as a notification of financing activity and related legal exhibits. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-04-03 English
424B5 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, related to an 'At The Market Offering' of common shares by InMed Pharmaceuticals Inc. It details the terms of the offering, the sales agreement with the sales agent, compensation, risk factors, and other offering-related information. It is not a financial report, earnings release, or management discussion, but rather a capital raising document describing a securities offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2026-04-03 English
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes standard 8-K headings such as Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. It announces positive data related to a drug program but does not contain detailed financial statements or comprehensive financial analysis. The document length is 3545 characters, which is relatively short and consistent with a current report rather than a full financial report. There is no indication that this is an earnings release, annual report, or interim report. The document is not a certification or a proxy statement. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-03-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.